News | Antiplatelet and Anticoagulation Therapies | November 03, 2017

Statins Attributed With 10-Year Cholesterol Drop for Malaysian Heart Attack Patients

Trend identified in study runs counter to Malaysian national trend of rising cholesterol

Statins Attributed With 10-Year Cholesterol Drop for Malaysian Heart Attack Patients

November 3, 2017 — A ten-year decline in the blood cholesterol of heart attack patients in Malaysia suggests statins are having a positive impact, according to an observational study in nearly 49,000 patients. The study was presented at the Association of Southeast Asian Nations (ASEAN) Federation of Cardiology Congress 2017 (AFCC2017).

AFCC2017 is being hosted by the Brunei Cardiac Society, with the support of the ASEAN Federation of Cardiology, Nov. 3-5 in Brunei Darussalam. Experts from the European Society of Cardiology (ESC) will present a special program.

“Lifestyle changes appear to be responsible for falls in blood cholesterol in the general populations of developed nations while statins have reduced cholesterol in patients with heart disease,” said lead author Sazzli Kasim, MBBCh, chair, Malaysian Society of Atherosclerosis and associate professor of medicine, University Technology MARA, Shah Alam, Malaysia.

“Blood cholesterol is still on the rise in the general population of developing countries like Malaysia,” he continued. “This study investigated trends in cholesterol levels in Malaysian patients with acute coronary syndromes.”

The study included 48,851 patients who had an acute coronary syndrome between 2006 and 2015 in Malaysia and were enrolled in the National Cardiovascular Disease Database Acute Coronary Syndrome (NCVD-ACS) Registry. This ongoing registry is maintained by the National Heart Association Malaysia with the support of the Ministry of Health Malaysia. Total cholesterol was assessed on entry to the registry.

The researchers examined trends in cholesterol levels of ACS patients over the ten-year period and compared them to previously published values for the entire population.

The investigators found a significant trend for declining total cholesterol from 2006 to 2015 in the ACS population (p =0.012). This was opposite to the total cholesterol trend in the Malaysian population.

ACS patients with a history of coronary heart disease had almost twice the declining rate in cholesterol as those with no history of coronary heart disease.

When the researchers examined total cholesterol by type of ACS, they found that patients with unstable angina had the lowest total cholesterol but the steepest rate of decline, followed by patients with non-ST-elevation myocardial infarction (NSTEMI) and then patients with ST-elevation myocardial infarction (STEMI).

Kasim said, “We found that blood cholesterol levels have been falling in Malaysian patients with acute coronary syndromes, which is the opposite of the national trend.”

“Since cholesterol levels have increased significantly in the Malaysian population as a whole, it is highly doubtful that lifestyle change is the reason for the declining cholesterol trend we observed in the ACS population,” he continued.

Kasim said, “While this was an observational study and we cannot infer causality, it seems likely that cholesterol levels decreased as the result of lipid lowering medication such as statins. ACS patients with a history of coronary heart disease, who were more likely to be taking statins, had a more rapid decline in cholesterol levels than those without a history of coronary heart disease.”

He concluded, “These results appear to mimic findings from developed countries in previous years and show that the Malaysian population is reaching similar health milestones. The findings also highlight the need to increase awareness of the harm of raised lipid values and the treatment available.”

Ezam Emran, scientific chair of AFCC2017, said, “This large study suggests that statins are being effectively used by heart attack patients in Malaysia. Rising lipid levels in the general population need to be tackled by promoting healthier lifestyles.”

Prof. Michel Komajda, a past president of the ESC and course director of the ESC program in Brunei, said: “The benefits of statins for preventing a second heart attack are unequivocal, as highlighted by the 2017 ESC guidelines. Patients should also be encouraged to quit smoking, adopt a healthier diet and be physically active.”

For more information: www.aseancardiology.org

Related Content

One-month Clopidogrel Monotherapy After PCI Not Supported in STOPDAPT-2 ACS Trial 
News | Antiplatelet and Anticoagulation Therapies | September 01, 2021
September 1, 2021 — The STOPDAPT-2 ACS trial does not support the use of one month of dual...
The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart attack or stroke in patients with AFib who undergo transcatheter aortic valve replacement (TAVR), according to an ESC late-breaking trial.

The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart attack or stroke in patients with AFib who undergo transcatheter aortic valve replacement (TAVR), according to an ESC late-breaking trial.

News | Antiplatelet and Anticoagulation Therapies | September 01, 2021
September 1, 2021 – The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart at
The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in patients with pre-existing cardiovascular disease who were taking 81 milligrams (mg) baby aspirin, versus 325 mg of daily aspirin. Getty Images #ACC #ACC21 #ACC2021

The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in patients with pre-existing cardiovascular disease who were taking 81 milligrams (mg) baby aspirin, versus 325 mg of daily aspirin. Getty Images

News | Antiplatelet and Anticoagulation Therapies | May 15, 2021
May 15, 2021 — The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in pat
A Chinese registry study found there are higher event rates in patients with shorter dual-antiplatelet therapy (DAPT) after PCI procedures. There has been a lot of movement toward using shorter duration DAPT with newer generation drug-eluting stent technologies, but this study reinforces the need longer DAPT in many patients. The findings were presented as a late-breaking trial at SCAI 2021 today. 

A Chinese registry study found there are higher event rates in patients with shorter dual-antiplatelet therapy (DAPT) after PCI procedures. There has been a lot of movement toward using shorter duration DAPT with newer generation drug-eluting stent technologies, but this study reinforces the need longer DAPT in many patients. The findings were presented as a late-breaking trial at SCAI 2021 today. 

News | Antiplatelet and Anticoagulation Therapies | April 28, 2021
April 28, 2021 — An analysis of the prospective Chinese Fuwai PCI Registry, confirms long-term,...
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can potentiate all 3 sides of Virchow’s Triad of coagulopathy, including endothelial dysfunction, blood flow stasis, and hypercoagulability. Angiotensin-converting enzyme-2 (ACE-2)–dependent viral entry and the virus-induced inflammatory response can lead to endothelial dysfunction. Clotting Prevention in COVID-19 Patients, Thrombosis Prevention in COVID-19 Patients, Preventing blood clots in COVID-19 patients

Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can potentiate all 3 sides of Virchow’s Triad of coagulopathy, including endothelial dysfunction, blood flow stasis and hypercoagulability. Angiotensin-converting enzyme-2 (ACE-2)–dependent viral entry and the virus-induced inflammatory response can lead to endothelial dysfunction. Additional figure included in the JACC article.

Feature | Antiplatelet and Anticoagulation Therapies | March 22, 2021 | By Dave Fornell, Editor
A comprehensive review or more than 80 randomized controlled trials (RCTs) investigating how to best manage optimal a
Tailor PCI trial showed genetic testing may play a role in personalizing antiplatelet therapy after PCI.
News | Antiplatelet and Anticoagulation Therapies | September 02, 2020
September 2, 2020 — An international, first-of-its-kind cardiology trial used personalized genetic testing to reduce